Last reviewed · How we verify
The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Castration-Resistant Heavily Pre-treated Prostate Cancer
The standard of care for men with metastatic CRPC in 2010 following progression on docetaxel is cabazitaxel or abiraterone acetate/prednisone. Based on results from two other studies, cabazitaxel and prednisone has become a standard second line chemotherapy regimen and becomes the backbone upon which to improve upon. Thus, the primary objective of this study is to determine the recommended dose of tasquinimod in combination with cabazitaxel and prednisone based on safety and tolerability in men with chemorefractory metastatic castration-resistant prostate cancer (CRPC).
Details
| Lead sponsor | Andrew J. Armstrong, MD |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 25 |
| Start date | 2012-01 |
| Completion | 2016-06 |
Conditions
- Prostate Cancer
Interventions
- tasquinimod
- tasquinimod 0.25 mg; 0.5 mg
- tasquinimod 0.25 mg; 0.5 mg; 1.0 mg
Primary outcomes
- Number of participants who experience dose limiting toxicities at the highest titrated dose for each dose level — 6 weeks
The primary objective is to determine the recommended dose of tasquinimod in combination with cabazitaxel and prednisone based on safety and tolerability in men with chemorefractory metastatic castration-resistant prostate cancer (CRPC).
Countries
United States